Fosun Pharma (600196.SH) subsidiary, Ding Acids Reel It Nib Capsule, has received approval for clinical trials.

The Zhitong Finance APP learned that Fosun Pharma (600196.SH) announced that its controlled subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. (referred to as "Fosun Wanbang"), recently received approval from the National Medical Products Administration (referred to as the "NMPA") to conduct clinical trials of its new drug, Fruquilatinib capsules (project code: SAF-189, application registration category: Class 1.1) for the adjuvant treatment of stage IB to IIIA non-small cell lung cancer patients with ALK or ROS1 positive tumors after radical resection. Fosun Wanbang plans to conduct Phase III clinical trials of the new drug in China (excluding mainland China, Hong Kong, Macau, and Taiwan) once the conditions are met.